DEMENTIA AND ALZHEIMER’S DISEASE TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Global Dementia and Alzheimer’s Disease Treatment Market Size and Forecast – 2025 to 2032

The Global Dementia and Alzheimer’s Disease Treatment Market is estimated to be valued at USD 13.10 Bn in 2025 and is expected to reach USD 23.19 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 8.5% from 2025 to 2032. The market is driven by the increasing prevalence of dementia and Alzheimer’s disease, the growing elderly population, and the development of novel therapies and diagnostic tools.

Key Takeaways of the Global Dementia and Alzheimer’s Disease Treatment Market:

• Cholinesterase inhibitors are expected to hold the largest market share, accounting for 29.2% in 2025, due to their proven effectiveness in managing Alzheimer's disease symptoms.
• Based on route of administration, the oral segment is projected to lead the global dementia and Alzheimer’s disease treatment market, contributing 32.2% in 2025.
• By distribution channel, the hospital pharmacies segment will represent the largest share of the market, with a an estimated contribution of 28.2% in 2025.
• North America is expected to lead the market, holding a share of 38.3% in 2025. Asia Pacific is anticipated to be the fastest-growing region, with a market share of 28.2% in 2025.

Market Overview:

The market trend for dementia and Alzheimer’s disease treatment is characterized by the focus on early diagnosis, the development of disease-modifying therapies, and the adoption of personalized medicine approaches. Pharmaceutical companies are investing heavily in research and development to identify new drug targets and develop innovative treatments that can slow down or halt the progression of the disease. Additionally, there is a growing emphasis on non-pharmacological interventions, such as cognitive stimulation therapy and lifestyle modifications, to improve the quality of life for patients and their caregivers.

Currents Events and their Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Analysis

To learn more about this report, Request sample copy

Dementia and Alzheimer’s Disease Treatment Market Insights, By Drug Class – Cholinesterase Inhibitors are Dominating Due to Proven Efficacy in Symptom Management

In terms of drug class, cholinesterase inhibitors contributes the highest share of the market with an estimated share of 29.2% in 2025 owing to their established efficacy in managing the symptoms of Alzheimer’s disease. These drugs work by inhibiting the breakdown of acetylcholine, a neurotransmitter crucial for memory and cognitive function. By maintaining higher levels of acetylcholine in the brain, cholinesterase inhibitors help to temporarily improve or stabilize the cognitive and functional abilities of patients with mild to moderate Alzheimer’s disease.

Drugs like Donepezil, Rivastigmine, and Galantamine have been extensively studied and have demonstrated their ability to enhance cognitive function, delay the progression of symptoms, and improve overall quality of life for patients.

For instance, the U.S. FDA has approved ALPHA-1062, marketed as Zunveyl, a next-generation acetylcholinesterase inhibitor developed by Alpha Cognition Inc., a biopharmaceutical company focused on neurodegenerative disorders. Zunveyl is a prodrug of galantamine designed to treat mild-to-moderate Alzheimer’s disease, offering improved tolerability and fewer gastrointestinal side effects.

Dementia and Alzheimer’s Disease Treatment Market Insights, By Route of Administration - Oral Drugs are Leading the Market Owing to Ease of Use and Better Patient Compliance

In terms of route of administration, the oral segment is expected to contribute the highest share of the global dementia and alzheimer’s disease treatment market with 32.2% in 2025. The oral route has several advantages that have made it the preferred choice for both patients and healthcare providers.

One of the key factors driving the growth of the oral segment is its convenience and ease of administration. Oral medications, such as tablets, capsules, and liquids, can be easily administered by patients or their caregivers in the comfort of their own homes. This eliminates the need for frequent visits to healthcare facilities for injections or infusions, which can be burdensome for patients and their families.

Dementia and Alzheimer’s Disease Treatment Market Insights, By Distribution Channel - Hospital Pharmacies Showcase Dominant as Primary Access Points for Diagnosis and Prescription Fulfilment

In terms of distribution channel, hospital pharmacies segment is expected to contribute the highest share of the global dementia and alzheimer’s disease treatment market with a share of 28.2% in 2025. Hospital pharmacies play a pivotal role in the distribution of Alzheimer’s disease medications, serving as the primary point of contact for patients and healthcare providers.

One of the main reasons for the high market share of hospital pharmacies is the specialized care and expertise they offer. Hospital pharmacies are staffed with trained professionals who have in-depth knowledge of Alzheimer’s disease treatments, including Cholinesterase Inhibitors, NMDA Receptor Antagonists, and other drug classes. These pharmacists can provide personalized medicine guidance to patients and their caregivers, ensuring proper medication use, dosing, and monitoring.

Reimbursement frameworks for Dementia and Alzheimer’s Disease Treatment Market

• Reimbursement for Alzheimer's and dementia care involves coordinated efforts between regulatory bodies, diagnostic coding systems, and insurance providers. In the U.S., Medicare leads structured coverage through CPT and HCPCS codes for cognitive assessments, imaging, and medication administration—such as Aduhelm and Lecanemab—requiring prior authorization and participation in CMS registries. Diagnostic validation includes MMSE or MoCA scores and serial testing, while international efforts like the WHO’s Global Action Plan and the EU’s ALCOVE initiative aim to standardize dementia care globally.
• Insurance coverage varies, with Medicare Part B covering infusions and assessments (20% coinsurance), while Medicaid funds long-term care with minimal out-of-pocket cost. Claims require strict documentation, including ICD-10 codes and cognitive test results, and are often subject to audits.
• For example, EmblemHealth’s reimbursement policy for Alzheimer’s and dementia care reflects this structured approach. It provides coverage for cerebrospinal fluid (CSF) amyloid beta peptide testing when there is documented clinical necessity, aligning with diagnostic validation requirements. However, it does not cover other biomarkers like tau protein in CSF or blood-based tests such as ApoE, due to insufficient evidence of clinical benefit.
• In practice, when a clinician submits a claim for anti-amyloid therapies like Aduhelm or Lecanemab under EmblemHealth, pre-authorization is mandatory and must include supporting biomarker results. The claim must also include ICD-10 codes for Alzheimer’s disease (e.g., G30.1) and documented cognitive scores. This mirrors Medicare’s broader policy that links reimbursement to clinical registries, cognitive testing, and strict documentation to ensure appropriate use and cost management.

Regional Insights

To learn more about this report, Request sample copy

North America Dementia and Alzheimer’s Disease Treatment Market Analysis and Trends

In North America, the dominance in the global dementia and Alzheimer’s disease treatment market with a share of 38.3% in 2025 can be attributed to several factors. The region boasts a well-established healthcare infrastructure, coupled with high awareness about neurodegenerative diseases among both healthcare professionals and the general population. The presence of leading pharmaceutical and biotech companies, such as Biogen, Eli Lilly, and Merck & Co., has further propelled the market growth in North America.  

For instance, in January 2024, Biogen announced plans to realign its resources to focus on advancing LEQEMBI (lecanemab-irmb) and developing new Alzheimer’s treatments, including BIIB080 (ASO targeting tau) and BIIB113 (oral tau aggregation inhibitor). These companies have been actively involved in the development of innovative therapies and diagnostic tools for dementia and Alzheimer’s disease. Moreover, favorable government policies, including increased funding for research and development activities and streamlined regulatory processes, have created a conducive environment for market growth in the region.

Asia Pacific Dementia and Alzheimer’s Disease Treatment Market Analysis and Trends

Meanwhile, the Asia Pacific region is expected to exhibit the fastest growth in the global dementia and Alzheimer’s disease treatment market with share of 28.2% in 2025. The rapid growth can be attributed to the increasing aging population, rising prevalence of dementia and Alzheimer’s disease, and growing awareness about these conditions. Countries like Japan, China, and South Korea have witnessed a significant increase in the elderly population, leading to a higher demand for effective treatment options.

Furthermore, governments in the region have been implementing various initiatives to improve healthcare infrastructure and increase access to advanced medical treatments. The expanding middle class and rising disposable incomes have also contributed to the market growth, as more people can afford quality healthcare services. Additionally, the presence of emerging players and increasing collaborations between global and local companies have further fueled the market growth in the Asia Pacific region.

Global Dementia and Alzheimer’s Disease Treatment Market Outlook for Key Countries:

U.S. Dementia and Alzheimer’s Disease Treatment Market Trends

The U.S. market for dementia and Alzheimer’s disease treatment is driven by a combination of factors, including a large aging population, high healthcare expenditure, and a strong focus on research and development. The country is home to several leading pharmaceutical companies, such as Biogen and Eli Lilly, which are actively involved in developing novel therapies for these conditions. The U.S. government has also been supportive of the market, with initiatives like the National Alzheimer’s Project Act (NAPA) aimed at accelerating research and improving care for individuals affected by Alzheimer’s disease.

For instance, in July 2024, Alpha Cognition announced that its oral therapy, ZUNVEYL (benzgalantamine), has received U.S. FDA approval for treating mild-to-moderate Alzheimer's disease. ZUNVEYLfeatures a dual mechanism of action designed to address gastrointestinal tolerability issues common with other Alzheimer’s medications, offering long-term efficacy and significant cognitive benefits. Alzheimer’s disease affects nearly 7 million people in the U.S. and is the leading cause of nursing home admissions and deaths.

Japan Dementia and Alzheimer’s Disease Treatment Market Trends

Japan's market for dementia and Alzheimer’s disease treatment is significantly influenced by its rapidly aging population, which is among the oldest in the world. The high prevalence of these conditions in the country has led to increased demand for effective treatment options.

For instance, according to data published by MJH Life Sciences in July 2024, as dementia cases rise globally, Japan is turning to digital solutions to support patients and caregivers. With nearly 10% of its population projected to face cognitive decline by 2030, the Japanese government is actively collaborating with technology companies to manage the burden. For example, Fujitsu and Hitachi are developing AI-driven tools for early detection and monitoring, while startups like Triple W Japan are offering wearable devices to assist elderly patients in daily tasks.

Germany Dementia and Alzheimer’s Disease Treatment Market Trends

Germany dementia and Alzheimer’s disease treatment market is projected to witness strong growth during the forecast period, driven by robust research initiatives and funding support. For instance, in September 2023, a study by the Robert Koch Institute forecasts an increase in dementia cases from 1.7 million in 2023 to 3 million by 2070.

The German Federal Ministry of Education and Research plays a leading role in advancing dementia research, while Germany also participates in international collaborations like the EU Joint Programme – Neurodegenerative Disease Research (JPND). The country’s global commitment is reflected in efforts to find an Alzheimer’s treatment by 2025 and in hosting major events such as ISAD-2025 in Berlin, underscoring its focus on combating dementia.

India Dementia and Alzheimer’s Disease Treatment Market Trends

India dementia and Alzheimer’s disease treatment market is projected to grow at the fastest pace during the forecast period, driven by its large patient base, rising elderly population, unmet clinical needs, and improving healthcare infrastructure. Research efforts in the country are focused on synaptic plasticity, novel molecule development, digital care solutions, and stem cell-based therapies. In October 2024, scientists at the Agharkar Research Institute in Pune, under the government of India, developed non-toxic, selective cholinesterase inhibitors using newly designed molecules, highlighting the country's progress in advancing Alzheimer’s treatment options.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Request sample copy

Key Developments:

• In April 2025, Eisai Co., Ltd. a Japanese pharmaceutical company and Biogen Inc., biotechnology company announced that the European Commission (EC) has granted marketing authorization (MA) for Leqembi (lecanemab), the first therapy in the EU to target the underlying cause of Alzheimer’s disease. Leqembi is approved for treating adult patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s, specifically for apolipoprotein E ε4 non-carriers or heterozygotes with confirmed amyloid pathology.
• In April 2025, Mayo Clinic launched a study to investigate the causes of rapidly progressive dementia (RPD) in patients with Alzheimer’s disease and Alzheimer’s Disease Related Dementias (ADRD). While most Alzheimer’s patients experience a gradual decline over years or decades, a small subset develops symptoms rapidly, leading to dementia within one year and complete incapacitation within two years.
• In March 2025, a clinical trial led by Mr. Randall J. Bateman, MD, at Washington University School of Medicine, suggests that an anti-amyloid drug can delay the onset of Alzheimer’s dementia if administered years before symptoms appear. The study, conducted on individuals with genetic predispositions for early-onset Alzheimer’s, showed that those who received the drug for an average of eight years had their risk of developing symptoms reduced from nearly 100% to about 50%.
• In January 2025, C2N Diagnostics, a leading company in neurological disease diagnostics, partnered with The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to explore the links between Alzheimer’s disease (AD), Lewy body dementia (LBD), and Parkinson’s disease (PD).

Top Strategies Followed by Global Dementia and Alzheimer’s Disease Treatment Market Players

• Established players in the global dementia and alzheimer’s disease treatment market are focusing on extensive research and development to innovate high-performance products. These companies are investing heavily in R&D to develop novel therapies, diagnostic tools, and care solutions to address the growing demand for effective treatments. For instance, leading pharmaceutical companies are working on developing disease-modifying drugs that target the underlying pathology of Alzheimer’s disease, such as amyloid plaques and tau tangles.
  • In July 2024, Eli Lilly and Company received U.S. FDA approval for Kisunla (donanemab-azbt), a once-monthly infusion treatment for early symptomatic Alzheimer's disease. In its Phase 3 study, Kisunla slowed cognitive and functional decline by up to 35% and reduced the risk of progression by 39%. The treatment targets amyloid plaques, removing up to 84% on average.

• Mid-level players in the market are adopting strategies focused on delivering cost-effective solutions to target price-sensitive consumers. They are developing generic versions of branded drugs and offering affordable diagnostic and care services. Additionally, collaborations with technology providers and production partners help these players boost their capabilities and expand their market reach.
  • In March 2025, BioClec, a biotechnology company co-founded by Dr. Marco Colonna, a leading expert in neuroimmunology and Alzheimer's research, launched with backing from Sofinnova Partners. Led by CEO Gabriella Camboni, a seasoned entrepreneur in biotech, BioClec is focused on developing innovative therapies targeting microglia, the brain's immune cells, to treat Alzheimer's disease.

• Small-scale players are targeting niche markets with unique features or innovative products. They are leveraging cutting-edge technologies, such as artificial intelligence and big data analytics, to develop personalized treatment plans and improve patient outcomes. Furthermore, local alliances with startups and regional manufacturers enable small players to gain market entry and visibility.
  • One such example is Lizzy Care, a health tech company that has developed an AI-driven platform for at-home dementia and memory care.The platform integrates predictive analytics, real-time care coordination, and local care management to enhance the quality of life for patients and families.In February 2025, Lizzy Care secured a USD 2.6 million seed funding round led by Boomerang Ventures, enabling the company to expand its innovative care platform and improve accessibility to high-quality dementia care.

Market Report Scope

Dementia and Alzheimer’s Disease Treatment Market Dynamics

To learn more about this report, Request sample copy

Dementia and Alzheimer’s Disease Treatment Market Driver - Increasing prevalence of dementia and Alzheimer’s disease

The global prevalence of dementia and Alzheimer’s disease is on the rise, primarily due to the aging population worldwide. As life expectancy continues to increase, the number of individuals affected by these neurodegenerative disorders is expected to grow significantly in the coming years. According to the World Health Organization (WHO), around 55 million people currently live with dementia globally, with nearly 10 million new cases emerging every year. Alzheimer’s disease, the most common form of dementia, accounts for 60-70% of these cases. The increasing burden of these conditions on healthcare systems and society as a whole is driving the demand for effective treatments and management strategies.

As a result, the global dementia and Alzheimer’s disease treatment market is experiencing substantial growth, with pharmaceutical companies and researchers focusing on developing novel therapies, diagnostic tools, and preventive measures to address this growing public health concern. For instance, in March 2025, according to data published by WHO, as of 2021, 57 million people worldwide have dementia, with Alzheimer’s disease making up 60-70% of cases. Dementia is the seventh leading cause of death, costing USD 1.3 trillion globally in 2019, half of which is due to informal caregiving. Women are more affected, providing 70% of care hours.

Dementia and Alzheimer’s Disease Treatment Market Opportunity - Advancements in drug development

The global dementia and alzheimer’s disease treatment market presents a promising opportunity driven by advancements in drug development. Researchers and pharmaceutical companies are actively engaged in the discovery and development of innovative therapeutic approaches to combat these neurological disorders. Recent progress in understanding the underlying pathological mechanisms of dementia and Alzheimer’s disease has paved the way for targeted drug therapies. Novel compounds, such as disease-modifying agents and symptomatic treatments, are being investigated to slow down or halt the progression of these conditions. Additionally, advancements in biomarker research and diagnostic tools enable earlier detection and intervention, expanding the window of opportunity for effective treatment.

For instance, on June 03, 2025, a report by Alzheimer's Research UK reveals that 138 drugs are currently being tested for Alzheimer’s disease, a nearly 9% increase from last year. This includes treatments for all stages of Alzheimer’s, from early to severe cases. Experts are hopeful that these trials will lead to safer, more effective medicines, building on recent advancements like lecanemab and donanemab. Notably, 48 drugs are in early-stage trials, including vaccines and engineered immune cells. However, recruitment challenges remain, with over 50,000 participants needed globally to complete trials.

Analyst Opinion (Expert Opinion)

• The dementia and Alzheimer’s disease treatment market is evolving rapidly, fueled by technological advancements in drug development, biomarkers, and diagnostic tools. Innovations such as the introduction of biologics and targeted therapies are driving the market, along with regulatory frameworks that expedite approval processes, particularly in regions like the U.S. and Europe. The growing incidence of dementia, attributed to the aging global population, is also a significant factor driving demand. However, the industry faces considerable challenges, including the complexity of Alzheimer’s pathology, limited treatment efficacy, and the high costs associated with clinical trials and drug development.
• Emerging opportunities within the market include the integration of artificial intelligence for early detection, the exploration of personalized medicine, and the potential for innovative care models that combine pharmacological and non-pharmacological treatments. Notable events, such as the Alzheimer’s Association International Conference (AAIC) and Dementia Care Conference, have played a pivotal role in fostering collaboration, advancing scientific research, and shaping policy. Initiatives like the U.S. National Plan to Address Alzheimer’s Disease and global research collaborations aim to address the growing demand for effective treatments and caregiving strategies, marking significant steps toward a comprehensive approach to tackling Alzheimer’s and dementia globally.

Market Segmentation

•  Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
• • Cholinesterase Inhibitors
    • Donepezil
    • Rivastigmine
    • Galantamine
  • NMDA Receptor Antagonists
    • Memantine
    • Amantadine
  • Antidepressants
    • Selective Serotonin Reuptake Inhibitors (SSRIs)
    • Tricyclic Antidepressants (TCAs)
  • Antipsychotics
    • Atypical Antipsychotics
    • Typical Antipsychotics
  • Disease-Modifying Therapies (DMTs)
    • Anti-Amyloid Monoclonal Antibodies
    • Protein Inhibitors
    • Anti-inflammatory Agents
  • Combination Drugs
    • Donepezil + Memantine (Namzaric)
    • Rivastigmine + Memantine
  • Others
•  Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
• • Oral
  • Parenteral
  • Transdermal
•  Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
• • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
•  Gender Insights (Revenue, USD Bn, 2020 - 2032)
• • Male
  • Female
•  Patient Demographics Insights (Revenue, USD Bn, 2020 - 2032)
• • Adults
  • Geriatrics
  • Pediatrics
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
• • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
• • Biogen Inc.
  • Eli Lilly and Company
  • Pfizer Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Roche Holding AG
  • Amgen Inc.
  • Sanofi S.A.
  • AstraZeneca PLC
  • Teva Pharmaceutical Industries Ltd.
  • Lundbeck A/S
  • Otsuka Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • AbbVie Inc.

Sources

Primary Research Interviews:

• Interviews with healthcare professionals specializing in neurology and geriatrics
• Discussions with pharmaceutical executives involved in dementia and Alzheimer’s treatment development
• Feedback from clinical trial coordinators and researchers in neurodegenerative diseases
• Insights from caregivers and patient advocacy groups
• Interviews with experts in AI and digital health applications for Alzheimer’s and dementia

Databases:

• World Health Organization (WHO) – Global Dementia Observatory
• U.S. National Institutes of Health (NIH) – Alzheimer’s Disease Research Center (ADRC)
• Centers for Disease Control and Prevention (CDC) – Alzheimer’s Disease and Healthy Aging Program
• European Medicines Agency (EMA) – Clinical Trials and Drug Development Guidelines
• U.S. National Institute on Aging (NIA) – Alzheimer’s Disease Facts and Figures
• Global Health Data Exchange (GHDx) – Data on global prevalence and healthcare spending on dementia

Magazines:

• Pharmaceutical Technology – Insights on drug development and regulatory processes in neurodegenerative diseases
• Neurobiology of Aging – Latest research findings on Alzheimer’s treatment and care
• Journal of Alzheimer’s Disease – A peer-reviewed journal dedicated to studies related to dementia and Alzheimer’s
• The Lancet Neurology – Articles related to clinical trials and breakthroughs in Alzheimer’s therapies
• Nature Reviews Neurology – Research and trends on dementia care and neurodegenerative disease treatments

Journals:

• Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association – Peer-reviewed research and articles focused on Alzheimer’s disease
• Journal of Neurochemistry – Research on neurodegeneration and therapeutic development for Alzheimer’s and dementia
• Frontiers in Aging Neuroscience – Open-access journal focused on aging-related neurological diseases, including Alzheimer’s
• Ageing Research Reviews – A journal exploring aging processes and therapies for neurodegenerative diseases
• Journal of Clinical Investigation – Articles on clinical trials and advancements in Alzheimer’s treatment

Newspapers:

• The New York Times – Reports on healthcare policies and developments in Alzheimer’s treatment and caregiving
• The Guardian – Coverage of global dementia initiatives and research advancements
• The Wall Street Journal – Business and financial analysis of the dementia and Alzheimer’s pharmaceutical market
• BBC News – Reports on global health issues, including dementia awareness and public health strategies
• Reuters – Updates on regulatory approvals and pharmaceutical advancements in dementia care

Associations:

• Alzheimer’s Association (AA) – Leading organization dedicated to advancing research and supporting individuals affected by Alzheimer’s
• International Alzheimer’s Disease International (ADI) – Provides global insights into Alzheimer’s disease prevalence, care, and advocacy
• European Federation of Neurological Associations (EFNA) – Works on neurological disorder treatment guidelines and dementia-related policies
• The International Society for the Study of the Aging Male (ISSAM) – Studies the impact of aging on dementia and cognitive disorders

Public Domain Sources:

• U.S. Census Bureau – Data on population aging, impacting Alzheimer’s disease prevalence
• Global Burden of Disease Study – Statistical data on the impact of dementia and Alzheimer’s worldwide
• United Nations Department of Economic and Social Affairs – Reports on aging populations and the societal burden of dementia
• National Institute on Aging (NIA) – Public domain resources on aging, Alzheimer’s research, and clinical trials
• National Library of Medicine – PubMed database for access to research articles and clinical studies on dementia treatments

Proprietary Elements:

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years